Skip to main content

Look SHARP

(well, maybe not)

Last week, results of the SHARP trial were released with great fanfare. In this study, investigators randomized over 9000 patients with chronic kidney disease (creatinine ≥ 1.7 mg/dL in men and ≥ 1.5 mg/dL in women) to placebo vs. a combination of ezetimibe and simvastatin, marketed under the brand name Vytorin. Over a median follow-up of 5 years, patients who received the study drug had a 1% lower risk of stroke and a 1.5% lower risk of requiring opening or bypassing a blocked artery in the heart or elsewhere. However, there was no difference in rates of heart attack, death from heart disease, or death from any cause.

What is extraordinary about this trial is not the mixed effect on outcomes, but the fact that it represents yet another wasted opportunity to learn whether ezetimibe actually has any clinical benefit. This drug, launched in the US in 2002, has enjoyed a meteoric rise in sales. By 2006, ezetimibe accounted for 15% of all prescriptions for cholesterol-lowering drugs, and in 2010 over $4 billion was spent on the drug. However, there is practically no data about whether ezetimibe yields any clinical benefit, either when given alone or when used to augment statin therapy.

In a list of clinical trials of ezetimibe, only one completed study to date has evaluated whether ezetimibe on top of a statin drug is better than the statin alone. This study, published in 2008, found that adding ezetimbe had no beneficial effect on a marker of atherosclerosis – and if anything, was slightly worse than the statin alone. Nearly all other completed trials have evaluated the combination of ezetimibe and simvastatin against placebo - which tells us almost nothing about whether adding ezetimibe on top of standard therapy provides any clinical benefit (or harm) above standard therapy alone.

In essence, enormous financial resources are put into trials whose main results clearly have much more value for increasing drug sales than for helping doctors learn the best ways to treat their patients. As a result, many billions of dollars are spent each year on unproven therapies, and millions of patients are exposed to drugs with unclear benefit. We can do better. We must.

P.S. For a succinct and thoughful commentary on the SHARP trial, click here.

Comments

ken covinsky said…
This study seems very concerning and raises serious questions about our obligations to research subjects. It seems this study design had clear advantages to the sponsor. If the study had shown a benefit from the drug, there would have been no way to know if patients should just get a statin or both ezetimide and statin. Most would have felt the need to give both in this circumstance. But it is quite obvious that the relevant question revolves around the comparison of the statin, both drugs, or placebo.

This seems to raise really important questions about the informed consent of research subjects. Is there an obligation to tell them that the study they are participating in will not address what most clinicians and experts view as the most important issues surrounding the study drug? Do they need to know that as a result of this, when the study is done, it is almost certain it will still not be known what the best treatment is? Do they also need to know that the optimal study is perfectly feasible but the sponsor has no interest in the learning the answer to the question posed by the optimal study?
I also wonder if the IRBs have a responsibility before approving to look at this aspect of trials. Maybe they need to consider if this the right trial to be doing? But that would take an expert in the topic field on each board (or maybe just consultant to each board?) to review the trial before approval.

Popular posts from this blog

The Future of Palliative Care: A Podcast with Diane Meier

There are few names more closely associated with palliative care than Diane Meier.  She is an international leader of palliative care, a MacArthur "genius" awardee, and amongst many other leadership roles, the CEO of the Center to Advance Palliative Care (CAPC).  We were lucky enough to snag Diane for our podcast to talk about everything we always wanted to ask her, including:
What keeps her up at night?Does palliative care need a national strategy and if so why and what would it look like?The history of CAPC and the leadership centersAdvice that she has for graduating fellows who want to continue to move palliative care forward as they start their new careersWhat she imagines palliative care will look like in 10 or 15 years?What is the biggest threat facing palliative care? So take a listen and if you want to dive a little deeper, here are two articles that we discussed during the podcast:
A National Strategy For Palliative Care. Health Affairs 2017Palliative Care Leadership…

Advance Care Planning before Major Surgery: A Podcast with Vicky Tang

This week's podcast is all about the intersection of geriatrics, palliative care, advanced care planning and surgery with our guest Dr. Vicky Tang.  Vicky is an assistant professor and researcher here at UCSF.  We talk about her local and national efforts focused on this intersection, including:
Her JAMA Surgery article that showed 3 out of 4 older adults undergoing high risk surgery had no advance care planning (ACP) documentation. Prehab clinics and how ACP fits into these clinicsThe Geriatric Surgery Verification Quality Improvement Program whose goal is to set the standards for geriatric surgical care including ACP discussions prior to surgeryHow frailty fits in and how to assess it (including this paper from JAGS on the value of the chair raise test) So take a listen and check out some of those links.  For those who want to take a deeper dive into how GeriPal and surgery fit together, check out these other podcasts: Zara Cooper on Trauma Surgery, Geriatrics, and Palliative Car…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …